- Home
- CYBN vs EPRX Comparison
CYBN vs EPRX Comparison
Compare CYBN & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- EPRX
- Stock Information
- Founded
- CYBN 2019
- EPRX 2011
- Country
- CYBN Canada
- EPRX Canada
- Employees
- CYBN N/A
- EPRX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- EPRX
- Sector
- CYBN Health Care
- EPRX
- Exchange
- CYBN Nasdaq
- EPRX NYSE
- Market Cap
- CYBN 127.3M
- EPRX 111.1M
- IPO Year
- CYBN N/A
- EPRX N/A
- Fundamental
- Price
- CYBN $6.95
- EPRX $3.90
- Analyst Decision
- CYBN Strong Buy
- EPRX Strong Buy
- Analyst Count
- CYBN 4
- EPRX 1
- Target Price
- CYBN $86.00
- EPRX $9.00
- AVG Volume (30 Days)
- CYBN 313.9K
- EPRX 10.5K
- Earning Date
- CYBN 06-25-2025
- EPRX 05-07-2025
- Dividend Yield
- CYBN N/A
- EPRX N/A
- EPS Growth
- CYBN N/A
- EPRX N/A
- EPS
- CYBN N/A
- EPRX N/A
- Revenue
- CYBN N/A
- EPRX N/A
- Revenue This Year
- CYBN N/A
- EPRX N/A
- Revenue Next Year
- CYBN N/A
- EPRX N/A
- P/E Ratio
- CYBN N/A
- EPRX N/A
- Revenue Growth
- CYBN N/A
- EPRX N/A
- 52 Week Low
- CYBN $4.81
- EPRX $2.20
- 52 Week High
- CYBN $14.44
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- CYBN 49.83
- EPRX N/A
- Support Level
- CYBN $6.83
- EPRX N/A
- Resistance Level
- CYBN $7.54
- EPRX N/A
- Average True Range (ATR)
- CYBN 0.65
- EPRX 0.00
- MACD
- CYBN 0.13
- EPRX 0.00
- Stochastic Oscillator
- CYBN 65.24
- EPRX 0.00
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.